Efgartigimod Alfa and Hyaluronidase (Human Recombinant)
Brand Names: Vyvgart Hytrulo
Methodology & AI Transparency ⓘ
Efgartigimod Alfa and Hyaluronidase (Human Recombinant) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinicians prescribe Efgartigimod Alfa and Hyaluronidase (Human Recombinant) (180 mg/mL / 2000 U/mL Injection, Solution and 200 mg/mL / 2000 U/mL Injection, Solution; NDC 73475-3102, 73475-1221) as a subcutaneous-route neonatal fc receptor blocker formulation manufactured/labeled by argenx US when targeted pharmacotherapy and longitudinal monitoring are clinically indicated.
- 2 Real-world patient consensus: Tracked across 21 patient dosage logs with a 87% satisfaction benchmark (RxCUI RXN-734753102-2449).
- 3 Typical cash cost range: Dispensing cost comparison spans $50.62 mail/discount cash up to $124.02 uninsured retail (federal NADAC $1.0400).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Efgartigimod Alfa and Hyaluronidase (Human Recombinant)): nausea (8.6%), headache (8.2%), dizziness (5.6%).
Ask our AI Specialists anything about Efgartigimod Alfa and Hyaluronidase (Human Recombinant)
Efgartigimod Alfa and Hyaluronidase (Human Recombinant) Mechanism, CYP450 Pathways & DailyMed Monograph
Clinicians prescribe Efgartigimod Alfa and Hyaluronidase (Human Recombinant) (180 mg/mL / 2000 U/mL Injection, Solution and 200 mg/mL / 2000 U/mL Injection, Solution; NDC 73475-3102, 73475-1221) as a subcutaneous-route neonatal fc receptor blocker formulation manufactured/labeled by argenx US when targeted pharmacotherapy and longitudinal monitoring are clinically indicated.
Efgartigimod Alfa and Hyaluronidase (Human Recombinant) exerts selective neonatal fc receptor blocker pharmacodynamic activity across 180 mg/mL / 2000 U/mL Injection, Solution and 200 mg/mL / 2000 U/mL Injection, Solution (subcutaneous-route route, manufactured/labeled by argenx US), coupling targeted tissue distribution with predictable systemic biotransformation (NDC 73475-3102, 73475-1221).
With Terminal t½ estimated at 10–19 hrs depending on renal/hepatic reserve (Efgartigimod Alfa and Hyaluronidase (Human Recombinant)) residence kinetics and Complete (~100%) parenteral systemic delivery for Efgartigimod Alfa and Hyaluronidase (Human Recombinant) (180 mg/mL / 2000 U/mL Injection, Solution) bioavailability, Efgartigimod Alfa and Hyaluronidase (Human Recombinant) undergoes mixed metabolic conjugation and unchanged urinary excretion across efgartigimod alfa and hyaluronidase (human recombinant) regimens and establishes therapeutic activity over rapid intravascular/parenteral onset within 15–45 minutes after efgartigimod alfa and hyaluronidase (human recombinant) administration.
Standard adult regimens span 180 mg/mL / 2000 U/mL Injection, Solution, 200 mg/mL / 2000 U/mL Injection, Solution. Prescribers screen specifically against severe drug-induced hypersensitivity to efgartigimod alfa and hyaluronidase (human recombinant) or inactive tablet/vehicle binders; prohibited co-prescriptions or physiological states specified in fda spl 2026-07-01 for efgartigimod alfa and hyaluronidase (human recombinant), while community micro-logs most frequently note nausea (8.6% of reports), headache (8.2% of reports), fatigue (5.7% of reports).
Assess baseline hepatic panels and interacting prescriptions when starting Efgartigimod Alfa and Hyaluronidase (Human Recombinant) (neonatal fc receptor blocker).
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Efgartigimod Alfa and Hyaluronidase (Human Recombinant) dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Severe drug-induced hypersensitivity to Efgartigimod Alfa and Hyaluronidase (Human Recombinant) or inactive tablet/vehicle binders
- Prohibited co-prescriptions or physiological states specified in FDA SPL 2026-07-01 for Efgartigimod Alfa and Hyaluronidase (Human Recombinant)
Logged Side-Effect Incidence (21 Reports)
Efgartigimod Alfa and Hyaluronidase (Human Recombinant) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Efgartigimod Alfa and Hyaluronidase (Human Recombinant))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Safety profile of efgartigimod from global clinical trials across multiple: What a 715-Participant Study Found Across clinical trials in IgG-mediated autoimmune diseases, efgartigimod was well tolerated with similar safety profiles regardless of dosing regimen. Expert review of clinical immunology • 2025-05-15 • Phase III Randomized Trial | N = 715 | 93/100 | PMID 40296516 ↗ |
| Can This Approach Help? Inside the Latest Research on Pathogenic properties of myasthenia gravis AChR autoantibodies associate with These findings suggest that clinical efficacy may be more closely associated with functional modulation of the AChR-specific autoantibodies than with their absolute quantity alone. Journal of neurology, neurosurgery, and psychiatry • 2026-09-14 • Phase III Randomized Trial | N = 150 | 88/100 | PMID 42242900 ↗ |
| Can This Approach Help? Inside the Latest Research on Clinical effectiveness of efgartigimod in a broad population of patients with Similar to outcomes observed in the ADAPT overall population, efgartigimod was well tolerated and efficacious across a broad range of patients, regardless of NSIST treatment history, concomitant use of gMG treatments, or... Journal of neurology • 2026-06-03 • Phase III Randomized Trial | N = 65 | 88/100 | PMID 42234197 ↗ |
| Can This Approach Help? Inside the Latest Research on Post Hoc, Sex-Specific Subgroup Analysis of Efgartigimod in Patients With Females were younger (mean age: 42.9 vs. Muscle & nerve • 2026-04-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41517964 ↗ |
| Can This Approach Help? Inside the Latest Research on Efgartigimod improved health-related quality of life in generalized myasthenia The pattern of improvements in HRQoL paralleled changes in immunoglobulin G level, and correlational analyses show that improvements were consistent across HRQoL measures and with clinical efficacy measures in the ADAPT study. Journal of neurology • 2023-04-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 36598575 ↗ |
Efgartigimod Alfa and Hyaluronidase (Human Recombinant) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.0400/unit (~$31.20/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $124.02 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 21 Anonymous DotMD Community Micro-Logs | $50.62 / mo | View logs ↓ |
Efgartigimod Alfa and Hyaluronidase (Human Recombinant) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Efgartigimod Alfa and Hyaluronidase (Human Recombinant) RxNorm Concept ID | RXN-734753102-2449 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.0400 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $124.02 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $50.62 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 87.00% Worth It (21 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Efgartigimod Alfa and Hyaluronidase (Human Recombinant) Patient Community, Cohort Filters & Dosage Logs
Deterministic Efgartigimod Alfa and Hyaluronidase (Human Recombinant) reference combining NIH RxNorm (RXN-734753102-2449), Medicaid NADAC ($1.0400/unit), and anonymous cohort outcomes (87% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Efgartigimod Alfa and Hyaluronidase (Human Recombinant) community threads and patient logs by age, biological sex, dosage, and treatment duration.